Viridian Therapeutics, Inc.\DE (VRDN) FCF Margin (2016 - 2025)
Historic FCF Margin for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to 120.08%.
- Viridian Therapeutics, Inc.\DE's FCF Margin rose 789485300.0% to 120.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 461.0%, marking a year-over-year increase of 649138300.0%. This contributed to the annual value of 77096.03% for FY2024, which is 181571700.0% down from last year.
- Latest data reveals that Viridian Therapeutics, Inc.\DE reported FCF Margin of 120.08% as of Q3 2025, which was up 789485300.0% from 100553.33% recorded in Q2 2025.
- In the past 5 years, Viridian Therapeutics, Inc.\DE's FCF Margin registered a high of 120.08% during Q3 2025, and its lowest value of 128804.17% during Q1 2025.
- Its 5-year average for FCF Margin is 44139.27%, with a median of 52844.44% in 2023.
- Examining YoY changes over the last 5 years, Viridian Therapeutics, Inc.\DE's FCF Margin showed a top increase of 789485300bps in 2025 and a maximum decrease of -659944400bps in 2025.
- Over the past 5 years, Viridian Therapeutics, Inc.\DE's FCF Margin (Quarter) stood at 7765.89% in 2021, then plummeted by -320bps to 32640.95% in 2022, then tumbled by -62bps to 52844.44% in 2023, then tumbled by -93bps to 102008.33% in 2024, then surged by 100bps to 120.08% in 2025.
- Its last three reported values are 120.08% in Q3 2025, 100553.33% for Q2 2025, and 128804.17% during Q1 2025.